EO 14297
Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients
HealthcareEconomy & TradeGovernment Reform
Ad Space (leaderboard)
Summary
This executive order directs the federal government to implement most-favored-nation (MFN) pricing for prescription drugs, requiring American patients to pay prices no higher than those charged in other developed nations. It establishes a 30-day timeline for HHS to communicate MFN price targets to pharmaceutical manufacturers and outlines escalating enforcement actions if manufacturers do not comply.
Key Points
- 1Requires HHS to establish and communicate most-favored-nation price targets to pharmaceutical manufacturers within 30 days to align U.S. drug prices with those in comparable developed countries
- 2Authorizes HHS to propose rulemaking to impose MFN pricing if manufacturers do not voluntarily comply with price targets
- 3Directs the FDA to consider certifying drug importation from developed nations with lower-cost drugs and to potentially modify or revoke drug approvals for non-compliant manufacturers
- 4Tasks the Secretary of Commerce and U.S. Trade Representative with investigating whether foreign price controls constitute unfair trade practices that harm American interests
- 5Instructs DOJ and FTC to pursue antitrust enforcement against anti-competitive pharmaceutical practices if identified
This summary is for informational purposes only. It may not capture all nuances of the executive order. Always refer to the official text for authoritative information.
Ad Space (rectangle)